Description: StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.
Home Page: www.stagezerolifesciences.com
70 East Beaver Creek Road
Richmond Hill,
ON
L4B 3B2
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. James R. Howard-Tripp | Exec. Chairman & CEO |
| Prof. Choong-Chin Liew | Co-Founder |
| Mr. Warren Whitehead C.M.A., CPA | Chief Accountant |
| Mr. David Suria | Sr. Scientist |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 3.4819 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.2177 |
| Price-to-Sales TTM: | 1.1689 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 80 |